Protein biotinylation.
Since its discovery in the first half of the twentieth century, the high-affinity, noncovalent interaction between biotin (vitamin H) and the avian protein avidin (and its bacterial homologs) has been exploited for many diverse biotechnology applications. This unit provides several basic protocols for labeling various protein reactive groups with biotin. These protocols can be applied not only to labeling in vitro or in tissue culture, but also to in vivo labeling of whole laboratory animals or to ex vivo labeling of surgically resected organs.
Elia
Giuliano
G
University College Dublin, Dublin, Ireland.
D000818:Animals; D001360:Avidin / Q000378:metabolism; D019921:Biotinylation; D006801:Humans; D008565:Membrane Proteins / Q000378:metabolism*; D051379:Mice; D008958:Models, Molecular
D008565:Membrane Proteins; D001360:Avidin
Bayer, E.A. and Wilchek, M. 1980. The use of the avidin-biotin complex as a tool in molecular biology. Methods Biochem. Anal 26:1-45.
Bayer, E.A., Skutelsky, E., and Wilchek, M. 1979. The avidin-biotin complex in affinity cytochemistry. Methods Enzymol. 62:308-315.
Bayer, E.A., Wilchek, M., and Skutelsky, E. 1976. Affinity cytochemistry: The localization of lectin and antibody receptors on erythrocytes via the avidin-biotin complex. FEBS Lett. 68:240-244.
Bayer, E.A., Viswanatha, T., and Wilchek, M. 1975. The use of a homologous series of affinity labeling reagents in the study of the biotin transport system in yeast cells. FEBS Lett. 60:309-312.
Becker, J.M. and Wilchek, M. 1972. Inactivation by avidin of biotin-modified bacteriophage. Biochim. Biophys. Acta 264:165-170.
Bogusiewicz, A., Mock, N.I., and Mock, D.M. 2004a. Instability of the biotin-protein bond in human plasma. Anal. Biochem. 327:156-161.
Bogusiewicz, A., Mock, N.I., and Mock, D.M. 2004b. Release of biotin from biotinylated proteins occurs enzymatically and nonenzymatically in human plasma. Anal. Biochem. 331:260-266.
Bogusiewicz, A., Mock, N.I., and Mock, D.M. 2005. A biotin-protein bond with stability in plasma. Anal. Biochem. 337:98-102.
Burg, M.B. and Orloff, J. 1964. Active cation transport by kidney tubules at O C. Am. J. Physiol. 207:983-988.
Castronovo, V., Kischel, P., Guillonneau, F., de Leval, L., Defechereux, T., De Pauw, E., Neri, D., and Waltregny, D. 2007. Identification of specific reachable molecular targets in human breast cancer using a versatile ex vivo proteomic method. Proteomics 7:1188-1196.
Castronovo, V., Waltregny, D., Kischel, P., Roesli, C., Elia, G., Rybak, J.N., and Neri, D. 2006. A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol. Cell. Proteomics 5:2083-2091.
Chen, Y., Chen, C., Wang, Y., and Liu-Chen, L.-Y. 2006. Ligands regulate cell surface level of the human {kappa} opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists. J. Pharmacol. Exp. Ther. 319:765-775.
Conrotto, P., Roesli, C., Rybak, J., Kischel, P., Waltregny, D., Neri, D., and Castronovo, V. 2008. Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int. J. Cancer 123:2856-64.
Cronan, J.E., Jr. 1990. Biotination of proteins in vivo: A post-translational modification to label, purify, and study proteins. J. Biol. Chem. 265:10327-33.
du Vigneaud, V., Hofmann, K., Melville, D.B., and Rachele, J.R. 1941. The preparation of free crystalline biotin. J. Biol. Chem. 140:763-766.
du Vigneaud, V., Melville, D.B., Folkers, K., Wolf, D.E., Mozingo, R., Keresztesy, J.C., and Harris, S.A. 1942. The structure of biotin: A study of desthiobiotin. J. Biol. Chem. 146:475-485.
Elia, G. 2008. Biotinylation reagents for the study of cell surface proteins. Proteomics 8:4012-4024.
Ellerbroek, S.M., Wu, Y.I., Overall, C.M., and Stack, M.S. 2001. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity. J. Biol. Chem. 276:24833-24842.
Fahey, R.C., Hunt, J.S., and Windham, G.C. 1977. On the cysteine and cystine content of proteins: Differences between intracellular and extracellular proteins. J. Mol. Evol. 10:155-160.
Forster, A.C., McInnes, J.L., Skingle, D.C., and Symons, R.H. 1985. Non-radioactive hybridization probes prepared by the chemical labelling of DNA and RNA with a novel reagent, photobiotin. Nucl. Acids Res. 13:745-761.
Foulon, C.F., Alston, K.L., and Zalutsky, M.R. 1997. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. Bioconjug. Chem. 8:179-186.
Goodman, J.W. 1991. Immunogenicity and antigenic specificity. In Basic Human Immunology. (D.P. Stites and A.I. Terr, eds.) pp. 101-108. Appleton & Lange, Los Altos, Calif.
Gottardi, C.J., Dunbar, L.A., and Caplan, M.J. 1995. Biotinylation and assessment of membrane polarity: Caveats and methodological concerns. Am. J. Physiol. 268:F285-95.
Lacey, E. and Grant, W.N. 1987. Photobiotin as a sensitive probe for protein labeling. Anal. Biochem. 163:151-158.
Melville, D.B., Moyer, A.W., Hofmann, K., and du Vigneaud, V. 1942. The structure of biotin: The formation of thiophenevaleric acid from biotin. J. Biol. Chem. 146:487-492.
Morag, E., Bayer, E.A., and Wilchek, M. 1996. Immobilized nitro-avidin and nitro-streptavidin as reusable affinity matrices for application in avidin-biotin technology. Anal. Biochem. 243:257-263.
Olejnik, J., Krzymanska-Olejnik, E., and Rothschild, K.J. 1996. Photocleavable biotin phosphoramidite for 5′-end-labeling, affinity purification and phosphorylation of synthetic oligonucleotides. Nucl. Acids Res. 24:361-366.
Orr, G.A. 1981. The use of the 2-iminobiotin-avidin interaction for the selective retrieval of labeled plasma membrane components. J. Biol. Chem. 256:761-766.
Parrott, M.B. and Barry, M.A. 2001. Metabolic biotinylation of secreted and cell surface proteins from mammalian cells. Biochem. Biophys. Res. Commun. 281:993-1000.
Peirce, M.J., Wait, R., Begum, S., Saklatvala, J., and Cope, A.P. 2004. Expression profiling of lymphocyte plasma membrane proteins. Mol. Cell. Proteomics 3:56-65.
Porwoll, S., Loch, N., Kannicht, C., Nuck, R., Grunow, D., Reutter, W., and Tauber, R. 1998. Cell surface glycoproteins undergo postbiosynthetic modification of their N-glycans by stepwise demannosylation. J. Biol. Chem. 273:1075-1085.
Reed, K.E. and Cronan, J.E., Jr. 1991. Escherichia coli exports previously folded and biotinated protein domains. J. Biol. Chem. 266:11425-11428.
Righi, M., Giacomini, A., Lavazza, C., Sia, D., Carlo-Stella, C. and Gianni, A.M. 2009. A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments. Lab. Invest. 89:1063-1070.
Roesli, C., Neri, D., and Rybak, J.N. 2006. In vivo protein biotinylation and sample preparation for the proteomic identification of organ- and disease-specific antigens accessible from the vasculature. Nat. Protoc. 1:192-199.
Rosebrough, S.F. 1993. Plasma stability and pharmacokinetics of radiolabeled deferoxamine-biotin derivatives. J. Pharmacol. Exp. Ther. 265:408-415.
Rösli, C., Rybak, J.-N., Neri, D., and Elia, G. 2007. Quantitative recovery of biotinylated proteins from streptavidin-based affinity chromatography resins. Methods Mol. Biol. 418:87-97.
Rybak, J.-N., Ettorre, A., Kaissling, B., Giavazzi, R., Neri, D., and Elia, G. 2005. In vivo protein biotinylation for the identification of organ-specific antigens accessible from the vasculature. Nat. Methods 2:291-298.
Rybak, J.N., Roesli, C., Kaspar, M., Villa, A., and Neri, D. 2007. The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res. 67:10948-10957.
Rybak, J.N., Scheurer, S.B., Neri, D., and Elia, G. 2004. Purification of biotinylated proteins on streptavidin resin: A protocol for quantitative elution. Proteomics 4:2296-2299.
Sabatino, G., Chinol, M., Paganelli, G., Papi, S., Chelli, M., Leone, G., Papini, A.M., De Luca, A., and Ginanneschi, M. 2003. A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J. Med. Chem. 46:3170-3173.
Sugio, S., Kashima, A., Mochizuki, S., Noda, M., and Kobayashi, K. 1999. Crystal structure of human serum albumin at 2.5 Å resolution. Protein Eng. 12:439-446.
Watkins, S. 1989. Cryosectioning. Curr. Protoc. Mol. Biol. 7:14.2.1-14.2.8.
Wilbur, D.S., Hamlin, D.K., Chyan, M.K., Kegley, B.B., and Pathare, P.M. 2001. Biotin reagents for antibody pretargeting. 5. Additional studies of biotin conjugate design to provide biotinidase stability. Bioconjug. Chem. 12:616-623.
Wilbur, D.S., Chyan, M.K., Pathare, P.M., Hamlin, D.K., Frownfelter, M.B., and Kegley, B.B. 2000a. Biotin reagents for antibody pretargeting. 4. Selection of biotin conjugates for in vivo application based on their dissociation rate from avidin and streptavidin. Bioconjug. Chem. 11:569-583.
Wilbur, D.S., Pathare, P.M., Hamlin, D.K., Frownfelter, M.B., Kegley, B.B., Leung, W.Y., and Gee, K.R. 2000b. Evaluation of biotin-dye conjugates for use in an HPLC assay to assess relative binding of biotin derivatives with avidin and streptavidin. Bioconjug. Chem. 11:584-598.
Wilbur, D.S., Pathare, P.M., Hamlin, D.K., Buhler, K.R., and Vessella, R.L. 1998. Biotin reagents for antibody pretargeting. 3. Synthesis, radioiodination, and evaluation of biotinylated starburst dendrimers. Bioconjug. Chem. 9:813-825.
Wilbur, D.S., Hamlin, D.K., Pathare, P.M., and Weerawarna, S.A. 1997. Biotin reagents for antibody pretargeting. Synthesis, radioiodination, and in vitro evaluation of water soluble, biotinidase resistant biotin derivatives. Bioconjug. Chem. 8:572-584.
Wilchek, M. and Bayer, E.A. 1987. Labeling glycoconjugates with hydrazide reagents. Methods Enzymol. 138:429-442.
Yu, M.-J., Pisitkun, T., Wang, G., Shen, R.-F., and Knepper, M.A. 2006. LC-MS/MS Analysis of apical and basolateral plasma membranes of rat renal collecting duct cells. Mol. Cell. Proteomics 5:2131-2145.